Idursulfase (brand name Elaprase), manufactured by Shire, is a drug used to treat Hunter syndrome (also called MPS-II). It is a purified form of the lysosomal enzyme iduronate-2-sulfatase and is produced by recombinant DNA technology in a human cell line.
It is one of the most expensive drugs ever produced, costing US$567,412 per patient per year.
- ^ Garcia AR, DaCosta JM, Pan J, Muenzer J, Lamsa JC (2007). "Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II". Mol. Genet. Metab. 91 (2): 183–90. PMID 17459751. doi:10.1016/j.ymgme.2007.03.003.
- ^ "Drug approved to treat rare but potentially deadly disease". Retrieved 2011-04-29.
- ^ Health Care: The World's Most Expensive Drugs, Matthew Herper, Forbes, Feb. 22, 2010
- ^ , Barbara Kollmeyer, Marketwatch, Fed. 3, 2016